TrialReader


CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

NCT03123783 — Phase 1 / Phase 2, Completed, 140 participants, Apexigen America, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma

RegistryNCT03123783
StatusCompleted
PhasePhase 1 / Phase 2
Study typeInterventional; non randomized, sequential, masking: none, treatment
Enrollment140 (Actual)
SponsorApexigen America, Inc. (Industry); collaborators: Bristol-Myers Squibb
ConditionsCancer, Non Small Cell Lung Cancer Metastatic, Metastatic Melanoma, Neoplasm of Lung, Melanoma
InterventionsAPX005M, Nivolumab (Drug)
Datesstart 2017-07-10, primary completion 2020-11-16, completion 2020-11-16, first posted 2017-04-21, last updated 2023-12-26
Locations23 sites in United States, Spain

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Cancer All trials for Non Small Cell Lung Cancer Metastatic All trials of APX005M All trials of Nivolumab

-Summary

This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.

Expand all sections  ·  Collapse all

+Detailed description

APX005M-002 is an open-label Phase 1-2 study and comprises a dose-escalation portion (Phase 1) followed by a Phase 2 tumor specific portion.

Eligible subjects with non-small cell lung cancer or metastatic melanoma will receive intravenous APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death, whichever occurs first.

Study objectives include:

* Determine the maximum tolerated dose and the recommended phase 2 dose of APX005M when given in combination with nivolumab
* Evaluate safety of the APX005M and nivolumab combination
* Evaluate the objective response rate, duration of response and median PFS by RECIST 1.1 in subjects with non-small cell lung cancer or metastatic melanoma receiving APX005M in combination with nivolumab
* Determine the PK of APX005M

+Arms and interventions

ArmTypeInterventionsDescription
Phase 1b escalation 0.03 mg/kgExperimentalDrug: APX005M; Drug: NivolumabNon-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.03 mg/kg and nivolumab 360 mg every 3 weeks
Phase 1b escalation 0.1 mg/kgExperimentalDrug: APX005M; Drug: NivolumabNon-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.1 mg/kg and nivolumab 360 mg every 3 weeks
Phase 1b escalation 0.3 mg/kgExperimentalDrug: APX005M; Drug: NivolumabNon-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks
Phase 2 expansion Cohort 1ExperimentalDrug: APX005M; Drug: NivolumabImmunotherapy naïve, metastatic or locally advanced NSCLC APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks
Phase 2 expansion Cohort 2ExperimentalDrug: APX005M; Drug: NivolumabMetastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks
Phase 2 expansion Cohort 3ExperimentalDrug: APX005M; Drug: NivolumabMetastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1: * Group A: best response of progressive disease or with stable disease < 16 weeks * Group B: tumor response or with stable disease ≥ 16 weeks
  • APX005M (Drug): APX005M is a CD40 agonistic monoclonal antibody
  • Nivolumab (Drug), also known as Opdivo: Nivolumab is an immune checkpoint (PD-1) blocking antibody

+Outcome measures

Primary outcomes

  • Number of Participants Experiencing Dose-limiting Toxicities (DLTs) [Up to 21 days following first dose of APX005M and nivolumab]: All toxicities were graded according to the NCI-CTCAE version 4.03. DLT was defined as any of the following events attributed to APX005M and nivolumab combination: * Grade 4 hematologic toxicity lasting ≥ 7 days (except asymptomatic lymphopenia) * Grade 3 or 4 neutropenia with a single temperature of >38.3◦ C (101◦ F) or a sustained temperature of ≥38◦ C (100.4◦ F) for more than one hour * Grade 4 thrombocytopenia or Grade ≥3 thrombocytopenia with signs or symptoms of bleeding or requiring platelet transfusion * Grade 4 non-hematologic toxicity * Grade 3 non-hematologic toxicity lasting >3 days despite optimal supportive care * Any Grade ≥ 3 non-hematologic laboratory value if: medical intervention is required to treat the subject, abnormality leads to hospitalization, or abnormality persists for >1 week * Failure to recover from a treatment-related AE to baseline or ≤ Grade 1 within 12 weeks of last dose of investigational product * Grade 5 toxicity.
  • Maximum Tolerated Dose (MTD) of APX005M + Nivolumab (Phase 1b) [Up to 21 days following first dose of APX005M and nivolumab]: Establish the MTD dose of APX005M combined with 360 mg of nivolumab for which for which < 33% of DLT- evaluable participants experience a DLT. In Phase 1b, the RP2D was based on the overall safety and tolerability of the combination of APX005M and nivolumab by testing increasing doses up to 0.3 mg/kg APX005M + nivolumab.
  • Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group [From start of the treatment (Day 1) until disease progression, withdrawal of consent, death, initiation of any anticancer therapy, lost to follow-up, or termination by the Sponsor, whichever comes first (for Phase 2: maximum up to 27 months)]: ORR defined as the rate of patients who show as best overall response; either a complete response (CR) or a partial response (PR). The ORR can be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. using computed tomography (CT) scans/magnetic resonance imaging (MRI). Per RECIST v1.1, for target lesions and assessed by imaging: Complete Response, (CR), Disappearance of all target lesions and nontarget (NT) lesions; Partial Response (PR), >30% decrease in the sum of the longest diameter of target lesions and no PD in NT lesions or new lesions; Objective Response Rate (ORR)=CR + PR.

Secondary outcomes

  • Safety of the APX005M and Nivolumab Combination (Phase 2) [Day 1 up to 30 days (or 100 days for SAEs and AEs with potential immunologic etiology) following the after the last dose of APX005M and/or nivolumab (from start of treatment up to 27 months)]: Number of participants with TEAEs are reported.
  • Duration of Response (DOR) as Per RECIST 1.1(Phase 2) [Maximum up to 25 months]: Duration of Response is defined as the time from the first evidence of confirmed partial response (PR) or better by Per RECIST v1.1 to disease progression or death due to any cause; in subjects alive without progressive disease (PD), DOR was censored on the date of the last tumor assessment. PD is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
  • Median Progression-free Survival (PFS) (Phase 2) [From start of treatment (Day 1) up to 27 months]: Progression-free Survival (PFS) in each cohort, measured from first dose to the earlier of PD (by RECIST 1.1) or death due to any cause, whichever occurs first.
  • 6-month PFS Rate (Phase 2) [* Outcome Measure Time Frame From start of treatment (Day 1) to 6 months]: PFS rate in each cohort, measured from first dose to the earlier of PD (by RECIST 1.1) or death due to any cause, whichever occurs first.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed
* Histologically or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD>=4 weeks later. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy.
* Measurable disease by RECIST 1.1
* ECOG performance status of 0 or 1
* Adequate bone marrow, liver and kidney function
* Negative pregnancy test for women of child bearing potential
* Agreement to use effective methods of contraception per the protocol requirements

Exclusion Criteria:

* Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy
* Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured
* Active, known, clinically serious infections within the 14 days prior to first dose of investigational product
* Use of systemic corticosteroids or other systemic immunosuppressive drugs
* Active, known or suspected autoimmune disease
* History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis
* History of interstitial lung disease
* History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC.

+Posted results

Participant flow

MilestoneDL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b)DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b)DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b)Cohort 1(Arm)/ inNSCLC (Phase 2)Cohort 2(Arm)/ PD1-MM (Phase 2) -Cohort 3A(Arm)/ PD1-NSCLC (Phase 2)Cohort 3B(Arm)/ PD1-NSCLC (Phase 2)
Started3430000
Participants in the safety population3330000
Participants in the efficacy population3330000
Completed3300000
Not completed0130000

Outcome results

  • Number of Participants Experiencing Dose-limiting Toxicities (DLTs) (Primary), Count of participants, Participants: Phase 1b Escalation 0
  • Maximum Tolerated Dose (MTD) of APX005M + Nivolumab (Phase 1b) (Primary), Number, mg/kg: Phase 1b Escalation NA
  • Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group (Primary), Number, Percentage of participants: Cohort 1 (Arm)/inNSCLC (Phase 2) 16.67 (8.57 to 28.07); Cohort 2(Arm)/PD1-MM (Phase 2) 15.15 (6.17 to 29.25); Cohort 3A(Arm)/PD1-NSCLC (Phase 2) 0.00 (0.00 to 22.09); Cohort 3B(Arm)/PD1-NSCLC (Phase 2) 0.00 (0.00 to 11.29)
  • Safety of the APX005M and Nivolumab Combination (Phase 2) (Secondary), Count of participants, Participants: Cohort 1 (Arm)/inNSCLC (Phase 2) 52; Cohort 2(Arm)/PD1-MM (Phase 2) 36; Cohort 3A(Arm)/PD1-NSCLC (Phase 2) 14; Cohort 3B(Arm)/PD1-NSCLC (Phase 2) 28
  • Duration of Response (DOR) as Per RECIST 1.1(Phase 2) (Secondary), Median, Months: Cohort 1(Arm)/inNSCLC (Phase 2) NA (3.9 to 21.4); Cohort 2(Arm)/PD1-MM (Phase 2) NA (4.2 to 24.7)
  • Median Progression-free Survival (PFS) (Phase 2) (Secondary), Median, Months: Cohort 1(Arm)/inNSCLC (Phase 2) 4.11 (3.45 to 5.52); Cohort 2(Arm)/PD1-MM (Phase 2) 1.97 (1.87 to 3.61); Cohort 3A(Arm)/PD1-NSCLC (Phase 2) 3.43 (2.00 to 3.88); Cohort 3B(Arm)/PD1-NSCLC (Phase 2) 3.65 (1.84 to 3.81)
  • 6-month PFS Rate (Phase 2) (Secondary), Number, Percentage of participants: Cohort 1(Arm)/inNSCLC (Phase 2) 33.10 (20.10 to 46.68); Cohort 2(Arm)/PD1-MM (Phase 2) 21.21 (9.35 to 36.25); Cohort 3A(Arm)/PD1-NSCLC (Phase 2) 25.00 (6.01 to 50.48); Cohort 3B(Arm)/PD1-NSCLC (Phase 2) 12.92 (3.27 to 29.41)

Adverse events

Time frame: Day 1 through 30 days (or 100 days for SAEs and AEs with potential immunologic etiology) after the last dose of study drug (up to 27 months)

ArmDeathsSerious adverse eventsOther adverse events
DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation)1/3 (33.3%)1/3 (33.3%)3/3 (100.0%)
DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation)1/3 (33.3%)1/3 (33.3%)3/3 (100.0%)
DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation)0/3 (0.0%)0/3 (0.0%)3/3 (100.0%)
Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL318/53 (34.0%)25/53 (47.2%)52/53 (98.1%)
Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL34/38 (10.5%)6/38 (15.8%)36/38 (94.7%)
Cohort 3A(Arm)/ PD1-NSCLC (Phase 2)4/14 (28.6%)6/14 (42.9%)14/14 (100.0%)
Cohort 3B(Arm)/ PD1-NSCLC (Phase 2)9/28 (32.1%)13/28 (46.4%)28/28 (100.0%)

Serious adverse events by term

TermOrgan systemDL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation)DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation)DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation)Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3Cohort 3A(Arm)/ PD1-NSCLC (Phase 2)Cohort 3B(Arm)/ PD1-NSCLC (Phase 2)
Acute coronary syndromeCardiac disorders0/30/30/32/530/380/140/28
Acute myocardial infarctionCardiac disorders0/30/30/31/530/380/140/28
Cardiac arrestCardiac disorders0/30/30/30/530/381/140/28
Cardio-respiratory arrestCardiac disorders0/30/30/31/530/380/140/28
Pericardial effusionCardiac disorders0/30/30/30/530/381/140/28
ConstipationGastrointestinal disorders0/30/30/31/530/380/140/28
GastritisGastrointestinal disorders0/30/30/30/530/380/141/28
Intestinal obstructionGastrointestinal disorders0/30/30/30/531/380/140/28
PancreatitisGastrointestinal disorders0/30/30/30/530/380/141/28
Pancreatitis acuteGastrointestinal disorders0/30/30/31/530/380/140/28
Facial painGeneral disorders0/30/30/31/530/380/140/28
General physical health deteriorationGeneral disorders0/30/30/31/530/380/141/28
PainGeneral disorders0/30/30/30/531/380/140/28
PyrexiaGeneral disorders0/31/30/31/530/380/140/28
Cytokine release syndromeImmune system disorders0/30/30/30/530/380/142/28
AppendicitisInfections and infestations0/30/30/30/531/380/140/28
BacteraemiaInfections and infestations0/30/30/30/531/380/141/28
BronchitisInfections and infestations0/30/30/30/530/380/141/28
InfuenzaInfections and infestations0/30/30/30/531/380/140/28
Lung abscessInfections and infestations0/30/30/31/530/380/140/28
Lung infectionInfections and infestations0/30/30/31/530/380/140/28
PneumoniaInfections and infestations0/31/30/34/530/382/142/28
SepsisInfections and infestations1/30/30/31/530/380/141/28
Streptococcal bacteraemiaInfections and infestations0/30/30/31/530/380/140/28
FallInjury, poisoning and procedural complications0/30/30/30/530/380/141/28
Femur fractureInjury, poisoning and procedural complications0/30/30/31/530/380/141/28
Hip fractureInjury, poisoning and procedural complications0/30/30/31/530/380/140/28
Radius fractureInjury, poisoning and procedural complications0/30/30/30/531/380/140/28
Toxicity to various agentsInjury, poisoning and procedural complications0/30/30/30/531/380/140/28
Blood bilirubin increasedInvestigations0/30/30/31/530/380/140/28
Weight decreasedInvestigations0/30/30/31/530/380/140/28
Diabetic ketoacidosisMetabolism and nutrition disorders0/30/30/31/530/380/140/28
HypercalcaemiaMetabolism and nutrition disorders0/30/30/30/530/380/141/28
HyperglycaemiaMetabolism and nutrition disorders0/30/30/30/530/380/141/28
ArthralgiaMusculoskeletal and connective tissue disorders0/30/30/30/530/380/141/28
Back painMusculoskeletal and connective tissue disorders0/30/30/31/530/380/140/28
MyositisMusculoskeletal and connective tissue disorders0/30/30/30/530/380/141/28
Bone neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/31/530/380/140/28
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/30/530/381/141/28
Brain oedemaNervous system disorders0/30/30/30/530/381/140/28
Cerebrovascular accidentNervous system disorders0/30/30/32/530/380/140/28
Encephalitis autoimmuneNervous system disorders0/30/30/30/530/381/140/28
SeizureNervous system disorders0/30/30/32/530/380/140/28
SyncopeNervous system disorders0/30/30/31/530/380/140/28
Confusional statePsychiatric disorders0/30/30/31/531/380/140/28
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/30/30/31/530/380/140/28
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/30/30/32/530/381/140/28
Chronic respiratory failureRespiratory, thoracic and mediastinal disorders0/30/30/31/530/380/140/28
DyspnoeaRespiratory, thoracic and mediastinal disorders0/30/30/32/530/381/142/28
Pleural effusionRespiratory, thoracic and mediastinal disorders0/30/30/32/530/380/140/28
PneumothoraxRespiratory, thoracic and mediastinal disorders0/30/30/31/530/380/140/28
Pulmonary artery thrombosisRespiratory, thoracic and mediastinal disorders0/30/30/31/530/380/140/28
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/30/30/33/530/381/142/28
Respiratory failureRespiratory, thoracic and mediastinal disorders0/30/30/31/530/380/140/28
Deep vein thrombosisVascular disorders0/30/30/30/530/381/140/28
Optic ischaemic neuropathyEye disorders0/31/30/30/530/380/140/28
Acute kidney injuryRenal and urinary disorders0/31/30/30/530/380/140/28
ColitisGastrointestinal disorders0/30/30/32/530/380/140/28

Other adverse events by term

TermOrgan systemDL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation)DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation)DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation)Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3Cohort 3A(Arm)/ PD1-NSCLC (Phase 2)Cohort 3B(Arm)/ PD1-NSCLC (Phase 2)
AnaemiaBlood and lymphatic system disorders0/32/30/313/534/380/146/28
PalpitationsCardiac disorders0/30/30/31/532/380/140/28
Sinus tachycardiaCardiac disorders0/30/30/33/531/380/141/28
TachycardiaCardiac disorders0/31/31/37/532/381/142/28
HyperthyroidismEndocrine disorders0/30/30/34/531/380/141/28
HypothyroidismEndocrine disorders1/30/31/35/532/381/140/28
Vision blurredEye disorders0/30/30/32/531/381/140/28
Abdominal painGastrointestinal disorders0/31/30/33/532/382/140/28
Abdominal pain upperGastrointestinal disorders0/30/30/30/531/383/141/28
ConstipationGastrointestinal disorders1/30/31/310/535/383/140/28
DiarrhoeaGastrointestinal disorders0/31/32/312/536/382/142/28
Dry mouthGastrointestinal disorders0/30/30/36/532/382/141/28
DyspepsiaGastrointestinal disorders0/30/30/30/532/380/140/28
DysphagiaGastrointestinal disorders0/30/30/30/531/380/142/28
NauseaGastrointestinal disorders1/31/33/324/5318/387/148/28
OdynophagiaGastrointestinal disorders0/30/30/30/530/380/142/28
StomatitisGastrointestinal disorders0/30/30/34/530/380/140/28
VomitingGastrointestinal disorders1/32/33/318/5310/382/145/28
AstheniaGeneral disorders0/30/30/37/536/384/1412/28
Chest discomfortGeneral disorders0/30/30/30/530/382/140/28
Chest painGeneral disorders0/30/30/32/531/380/145/28
ChillsGeneral disorders0/32/33/330/5319/385/1413/28
FatigueGeneral disorders3/32/30/318/5315/385/144/28
MalaiseGeneral disorders0/30/31/32/534/383/140/28
Non-cardiac chest painGeneral disorders0/30/30/35/530/380/140/28
Oedema peripheralGeneral disorders0/32/30/34/533/383/142/28
PainGeneral disorders1/31/30/35/531/380/141/28
PyrexiaGeneral disorders0/32/32/328/5326/387/1412/28
Cytokine release syndromeImmune system disorders0/31/30/33/530/380/141/28
NasopharyngitisInfections and infestations0/30/30/33/531/380/142/28
PneumoniaInfections and infestations0/30/30/36/530/380/140/28
Respiratory tract infectionInfections and infestations0/30/30/31/530/380/144/28
SinusitisInfections and infestations0/30/30/31/530/380/142/28
Upper respiratory tract infectionInfections and infestations0/30/30/32/534/382/140/28
Urinary tract infectionInfections and infestations0/30/30/32/532/380/140/28
FallInjury, poisoning and procedural complications0/30/30/34/530/380/140/28
Infusion related reactionInjury, poisoning and procedural complications0/30/30/35/533/382/143/28
Alanine aminotransferase increasedInvestigations0/31/30/311/5311/384/148/28
Blood alkaline phosphataseInvestigations0/30/30/30/530/382/140/28
Blood alkaline phosphatase increasedInvestigations0/31/30/39/537/381/143/28
Blood bilirubin increasedInvestigations1/30/31/33/533/380/141/28
Blood creatinine increasedInvestigations0/30/30/35/531/381/141/28
Blood lactate dehydrogenase increasedInvestigations0/30/30/30/533/380/141/28
Gamma-glutamyltransferase increasedInvestigations0/30/30/38/537/384/145/28
Haemoglobin decreasedInvestigations0/30/30/31/531/380/143/28
Lipase increasedInvestigations0/30/30/35/531/380/140/28
Platelet count decreasedInvestigations0/30/30/34/531/380/140/28
Weight decreasedInvestigations0/31/30/314/530/381/143/28
Decreased appetiteMetabolism and nutrition disorders1/32/31/314/534/384/147/28
DehydrationMetabolism and nutrition disorders0/31/30/35/530/380/141/28
HypercalcaemiaMetabolism and nutrition disorders0/30/30/31/530/380/142/28
HyperglycaemiaMetabolism and nutrition disorders0/31/30/34/531/380/140/28
HypokalaemiaMetabolism and nutrition disorders0/30/30/34/530/380/142/28
HypomagnesaemiaMetabolism and nutrition disorders0/30/30/33/530/380/141/28
HyponatraemiaMetabolism and nutrition disorders1/30/30/34/531/380/141/28
ArthralgiaMusculoskeletal and connective tissue disorders1/31/31/312/536/383/145/28
Back painMusculoskeletal and connective tissue disorders1/31/30/38/534/381/142/28
Bone painMusculoskeletal and connective tissue disorders0/30/30/33/530/380/141/28
Flank painMusculoskeletal and connective tissue disorders0/30/30/33/530/380/141/28
Muscular weaknessMusculoskeletal and connective tissue disorders0/30/30/34/530/380/140/28

95 more terms not shown.

Limitations and caveats: In the AE section, DL3 participant data had no DLTs; AE data collected from DL3 was also added to Phase 2.

+Locations (23)

FacilityCityCountryStatus
University of Arizona Cancer CenterTucson, ArizonaUnited States
City of HopeDuarte, CaliforniaUnited States
Yale UniversityNew Haven, ConnecticutUnited States
Hem-Onc Associates of the Treasure CoastPort Saint Lucie, FloridaUnited States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC)Baltimore, MarylandUnited States
Nebraska Cancer SpecialistsOmaha, NebraskaUnited States
University of Nebraska Medical CenterOmaha, NebraskaUnited States
SUNY Upstate Medical HospitalSyracuse, New YorkUnited States
University Hospitals Seidman Cancer CenterCleveland, OhioUnited States
Abramson Cancer Center of The University of PennsylvaniaPhiladelphia, PennsylvaniaUnited States
Fox Chase Cancer CenterPhiladelphia, PennsylvaniaUnited States
Fox Chase CenterRockledge, PennsylvaniaUnited States
Tennessee OncologyNashville, TennesseeUnited States
Hospital Quirón DexeusBarcelonaSpain
H. Vall d'HebronBarcelonaSpain
H. Clinic i ProvincialBarcelonaSpain
H. Insular de Gran CanariaLas Palmas de Gran CanariaSpain
H. Lucus AugustiLugoSpain
H. Doce de OctubreMadridSpain
H. HM SanchinnarroMadridSpain
H. de MálagaMálagaSpain
H. La FeValenciaSpain
H. General de ValenciaValencia de AlcántaraSpain

+Study documents

+Investigators

  • Medical Director, Study director, Pyxis Oncology, Inc

My Notes